The PI3Kδ inhibitor idelalisib suppresses liver and lung cellular respiration

Idelalisib (an inhibitor of phosphatidylinositol-3-kinase-delta) is approved for treatment of B-cell malignancies, with a Boxed Warning concerning potentially fatal hepatic, lung, and intestinal toxicities. The mechanisms of these tissue-specific adverse events have yet to be elucidated. This in vit...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Physiol Pathophysiol Pharmacol
Egile Nagusiak: Hammadi, Suleiman Al, Almarzooqi, Saeeda, Abdul-Kader, Hidaya Mohammed, Saraswathiamma, Dhanya, Souid, Abdul-Kader
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: e-Century Publishing Corporation 2015
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4697667/
https://ncbi.nlm.nih.gov/pubmed/26823960
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak